BR112019003637A2 - um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino - Google Patents
um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino Download PDFInfo
- Publication number
- BR112019003637A2 BR112019003637A2 BR112019003637A BR112019003637A BR112019003637A2 BR 112019003637 A2 BR112019003637 A2 BR 112019003637A2 BR 112019003637 A BR112019003637 A BR 112019003637A BR 112019003637 A BR112019003637 A BR 112019003637A BR 112019003637 A2 BR112019003637 A2 BR 112019003637A2
- Authority
- BR
- Brazil
- Prior art keywords
- disubstituted
- steroid
- pyrazolyl
- crystalline
- formula
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 3
- 239000007787 solid Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 | |
| PCT/US2017/048267 WO2018039378A1 (en) | 2016-08-23 | 2017-08-23 | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019003637A2 true BR112019003637A2 (pt) | 2019-08-06 |
Family
ID=59772778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019003637A BR112019003637A2 (pt) | 2016-08-23 | 2017-08-23 | um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US11236121B2 (enExample) |
| EP (2) | EP3981763A1 (enExample) |
| JP (3) | JP2019524853A (enExample) |
| KR (2) | KR20230079470A (enExample) |
| CN (4) | CN115974956A (enExample) |
| AR (3) | AR109393A1 (enExample) |
| AU (3) | AU2017315682B2 (enExample) |
| BR (1) | BR112019003637A2 (enExample) |
| CA (1) | CA3034262A1 (enExample) |
| CL (2) | CL2019000477A1 (enExample) |
| CO (1) | CO2019002596A2 (enExample) |
| EA (1) | EA201990565A1 (enExample) |
| EC (1) | ECSP19020141A (enExample) |
| IL (2) | IL302480A (enExample) |
| JO (1) | JOP20190022B1 (enExample) |
| MA (1) | MA46042A (enExample) |
| MX (2) | MX393240B (enExample) |
| MY (1) | MY200479A (enExample) |
| NZ (1) | NZ791594A (enExample) |
| PE (2) | PE20241580A1 (enExample) |
| PH (1) | PH12019500375A1 (enExample) |
| SG (1) | SG11201901445TA (enExample) |
| TW (2) | TWI854445B (enExample) |
| WO (1) | WO2018039378A1 (enExample) |
| ZA (1) | ZA201901051B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2766380T (pt) | 2011-10-14 | 2019-07-29 | Sage Therapeutics Inc | Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos |
| EP2887944B1 (en) | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone for treating refractory status epilepticus |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| KR102614507B1 (ko) | 2013-04-17 | 2023-12-19 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| PL2986624T3 (pl) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia |
| CA3199003A1 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| HUE052308T2 (hu) | 2013-08-23 | 2021-04-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásuk |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP3206493B1 (en) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CN117024502A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| KR20230079470A (ko) | 2016-08-23 | 2023-06-07 | 세이지 테라퓨틱스, 인크. | 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| US20200281943A1 (en) * | 2017-09-07 | 2020-09-10 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| IL303083A (en) * | 2017-09-14 | 2023-07-01 | Sage Therapeutics Inc | 19-NOR C3,3-C21-N-pyrazolyl steroid dimer and methods of using it |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| CN117959309A (zh) * | 2018-06-12 | 2024-05-03 | 萨奇治疗股份有限公司 | 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| MX2021006618A (es) | 2018-12-05 | 2021-09-23 | Sage Therapeutics Inc | Esteroides neuroactivos y sus metodos de uso. |
| CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| CN111770915A (zh) * | 2019-01-31 | 2020-10-13 | 深圳仁泰医药科技有限公司 | γ-氨基丁酸调节剂的晶型X及其制备方法和应用 |
| US20220220149A1 (en) | 2019-05-28 | 2022-07-14 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| WO2020243488A1 (en) | 2019-05-31 | 2020-12-03 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
| US20220275020A1 (en) * | 2019-08-07 | 2022-09-01 | Shanghai Hansoh Biomedical Co., Ltd. | Salt and crystal form of steroid derivative regulator |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| BR112023000990A2 (pt) * | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
| WO2022072620A1 (en) * | 2020-10-01 | 2022-04-07 | Eliem Therapeutics (UK) Ltd | Methods of treating fibromyalgia with neuroactive steroids |
| JP2024507638A (ja) | 2021-01-28 | 2024-02-21 | セージ セラピューティクス， インコーポレイテッド | 性機能障害処置のための神経刺激性ステロイドの使用 |
| CA3213744A1 (en) | 2021-03-17 | 2022-09-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| WO2022232494A1 (en) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| IL307991A (en) | 2021-04-29 | 2023-12-01 | Sage Therapeutics Inc | 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression |
| KR20240037975A (ko) | 2021-07-28 | 2024-03-22 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드의 결정질 형태 |
| KR20240148425A (ko) | 2022-02-16 | 2024-10-11 | 세이지 테라퓨틱스, 인크. | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| AU2930501A (en) * | 2000-01-07 | 2001-07-24 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| CN1323074C (zh) | 2002-02-08 | 2007-06-27 | 小野药品工业株式会社 | 哌啶衍生物以及包含哌啶衍生物作为活性成分的药物组合物 |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| PT2766380T (pt) | 2011-10-14 | 2019-07-29 | Sage Therapeutics Inc | Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos |
| RS59734B1 (sr) | 2012-01-23 | 2020-02-28 | Sage Therapeutics Inc | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina |
| WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| EP2887944B1 (en) | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone for treating refractory status epilepticus |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP2925327B1 (en) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
| KR102400891B1 (ko) | 2012-12-18 | 2022-05-20 | 워싱톤 유니버시티 | 신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법 |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| KR102614507B1 (ko) | 2013-04-17 | 2023-12-19 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| PL2986624T3 (pl) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia |
| CA3199003A1 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| HUE052308T2 (hu) | 2013-08-23 | 2021-04-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásuk |
| ES2927007T3 (es) | 2014-05-29 | 2022-10-31 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN117024502A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| EP3206493B1 (en) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| US20180311258A1 (en) | 2015-04-10 | 2018-11-01 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| EP3347368A4 (en) | 2015-09-08 | 2019-01-23 | Viewpoint Therapeutics, Inc. | COMPOUNDS AND FORMULATIONS FOR THE TREATMENT OF EYE DISEASES |
| EA036155B1 (ru) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
| WO2017087864A1 (en) | 2015-11-20 | 2017-05-26 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| AU2017229656B2 (en) | 2016-03-08 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| KR20230079470A (ko) | 2016-08-23 | 2023-06-07 | 세이지 테라퓨틱스, 인크. | 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| CA3073925A1 (en) | 2017-08-31 | 2019-03-07 | Takeda Pharmaceutical Company Limited | Treatment of cns conditions |
| US20200281943A1 (en) | 2017-09-07 | 2020-09-10 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| IL303083A (en) | 2017-09-14 | 2023-07-01 | Sage Therapeutics Inc | 19-NOR C3,3-C21-N-pyrazolyl steroid dimer and methods of using it |
| US20190160078A1 (en) | 2017-11-10 | 2019-05-30 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disorders |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| JP2021506904A (ja) | 2017-12-22 | 2021-02-22 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害の処置のための組成物および方法 |
| EP3728284B1 (en) | 2017-12-22 | 2024-08-21 | Sage Therapeutics, Inc. | 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders |
| JP7538040B2 (ja) | 2018-01-12 | 2024-08-21 | セージ セラピューティクス， インコーポレイテッド | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
| CN117959309A (zh) | 2018-06-12 | 2024-05-03 | 萨奇治疗股份有限公司 | 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| JP7671244B2 (ja) | 2018-10-12 | 2025-05-01 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド |
| EP3867261B1 (en) | 2018-10-19 | 2025-04-30 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| MX2021006618A (es) | 2018-12-05 | 2021-09-23 | Sage Therapeutics Inc | Esteroides neuroactivos y sus metodos de uso. |
| WO2020132504A1 (en) | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| WO2020243488A1 (en) | 2019-05-31 | 2020-12-03 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
| JP7670632B2 (ja) | 2019-06-27 | 2025-04-30 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を治療するための組成物及び方法 |
| US20230303616A9 (en) | 2019-06-27 | 2023-09-28 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2020264495A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| KR20220112803A (ko) | 2019-12-05 | 2022-08-11 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| WO2021188778A2 (en) | 2020-03-18 | 2021-09-23 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| JP2023531517A (ja) | 2020-06-24 | 2023-07-24 | セージ セラピューティクス， インコーポレイテッド | ３．アルファ．－ヒドロキシ、１７．ベータ．－ｃ（ｏ）－ｎ－アリール置換神経活性ステロイド及びそれらの組成物 |
| BR112023000990A2 (pt) | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
| CA3202870A1 (en) | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JP2024507638A (ja) | 2021-01-28 | 2024-02-21 | セージ セラピューティクス， インコーポレイテッド | 性機能障害処置のための神経刺激性ステロイドの使用 |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| CA3213744A1 (en) | 2021-03-17 | 2022-09-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| CA3216542A1 (en) | 2021-04-12 | 2022-10-20 | Sage Therapeutics, Inc. | Treatment of essential tremor |
| WO2022232494A1 (en) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| IL307991A (en) | 2021-04-29 | 2023-12-01 | Sage Therapeutics Inc | 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression |
| KR20240148425A (ko) | 2022-02-16 | 2024-10-11 | 세이지 테라퓨틱스, 인크. | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
-
2017
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko active Pending
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/en active Pending
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 NZ NZ791594A patent/NZ791594A/en unknown
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 CA CA3034262A patent/CA3034262A1/en active Pending
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt not_active Application Discontinuation
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/en not_active Withdrawn
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Ceased
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 MX MX2019002193A patent/MX393240B/es unknown
- 2017-08-23 MY MYPI2019000844A patent/MY200479A/en unknown
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es not_active Application Discontinuation
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 PE PE2024000634A patent/PE20241580A1/es unknown
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 TW TW112101437A patent/TWI854445B/zh active
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 IL IL315950A patent/IL315950A/en unknown
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/en not_active Ceased
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
-
2023
- 2023-08-24 US US18/455,324 patent/US12358942B2/en active Active
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732A1/en active Pending
- 2024-05-07 JP JP2024075299A patent/JP2024097878A/ja active Pending
-
2025
- 2025-06-11 US US19/234,808 patent/US20250304615A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019003637A2 (pt) | um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino | |
| CY1123295T1 (el) | Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης | |
| TR2021016542A2 (tr) | Plazma bazlı filmler ve bunları üretme ve kullanma usulleri. | |
| MX387736B (es) | Derivados de fenoximetilo. | |
| DK3684333T3 (da) | Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil | |
| JOP20190174B1 (ar) | مثبطات jak1 انتقائية | |
| MX393879B (es) | Métodos de preparación de niraparib. | |
| MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
| JOP20170100B1 (ar) | توليف مركبات إندازول | |
| MX2019011758A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| EA201890898A1 (ru) | Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение | |
| CY1125352T1 (el) | Κρυσταλλικες ενωσεις | |
| TR201821116A2 (tr) | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ | |
| PH12017501280A1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
| EA201891342A1 (ru) | Изоиндольные соединения | |
| CY1124056T1 (el) | Κρυσταλλικες μορφες της μηλεϊνικης 1-((2r, 4r)-2-(1η-βενζο[d] iμιδαζολ-2-υλο)-1-μεθυλοπιπεριδιν-4-υλο)-3-(4-κυανοφαινυλ) ουριας | |
| ZA201803476B (en) | Anti-cd22 antibody-maytansine conjugates and methods of use thereof | |
| EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
| JOP20190163B1 (ar) | منشط nrf2 | |
| MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
| EA201892235A1 (ru) | Гранулированная композиция для перорального применения | |
| EA201691493A1 (ru) | Замещенные n-арилпиридиноны | |
| PH12017501869A1 (en) | (s)-2'-vinyl-abscisic acid derivatives | |
| MX2021015879A (es) | Peptidos restringidos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024016003-0 PROTOCOLO 870240066309 EM 05/08/2024 17:09.O PEDIDO FOI DIVIDIDO NO BR122024016008-0 PROTOCOLO 870240066331 EM 05/08/2024 17:24. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |